GSK shares jump on $2.2 billion Zantac settlement
Settlement resolves 80,000 or 93% of pending US cases
GSK top gainer on FTSE-100, best one-day gain since Dec 2022
To record 1.8 billion pounds charge in Q3 results
Rewrites paragraphs 1-3, adds investor comment in 4-5
By Maggie Fick and Yamini Kalia
Oct 10 (Reuters) -GSK GSK.L shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
The deal, announced on Wednesday, was far lower than many analysts and investors had expected, including JP Morgan's projection of $3.5 billion. Barclays analysts described it as a "best case scenario in terms of aggregate settlement".
The deal resolves 80,000, or 93%, of the pending cases against the company in the United States. Analysts at Jefferies and elsewhere said the news removed most of the overhang on the stock from the issue, which has dogged GSK for over two years.
"The settlement of $2.2 billion is lower than market expectations of $3.5 billion, and the announcement came sooner than expected. The Zantac clouds are lifting, and GSK will likely resolve the few remaining cases quickly," said Lucy Coutts, investment director at wealth management firm JM Finn, which holds GSK shares.
"Importantly, its core earnings are unaffected so investors can now focus on GSK delivering on its late-stage pipeline", Coutts told Reuters.
Concerns about lawsuits and potential compensation wiped almost $40 billion off the combined market values of GSK, Sanofi SASY.PA, Pfizer PFE.N and Haleon HLN.L, which all also sold the drug, over roughly a week in August 2022.
GSK shares were the top gainers on the FTSE benchmark .FTSE index on Thursday and on track for their best one-day percentage gain since December 2022.
The company will also pay $70 million to settle a related whistleblower lawsuit filed by a Connecticut laboratory.
GSK admitted no wrongdoing or liability in the settlements, and said they were in the best long-term interest of the company to avoid the risk of continuing litigation.
The company expects to record a 1.8 billion pound ($2.4 billion) charge in its third quarter results due to the settlements, with no impact seen on its investment plans.
It will announce third quarter results on Oct. 30.
First approved by U.S. regulators in 1983, Zantac became the world's best-selling medicine in 1988 and one of the first to top $1 billion in annual sales. The drug was sold at different times by GSK, Pfizer, Sanofi and Boehringer Ingelheim.
Ranitidine, which was sold under the Zantac brand name, was pulled off the market in 2020 on concerns it could degrade into NDMA, a carcinogen, over time or when exposed to heat. The recall triggered a spate of lawsuits.
($1 = 0.7642 pounds)
Reporting by Yamini Kalia in Bengaluru; Editing by Sharon Singleton and Mark Potter
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
